4CPS-128 Effectiveness of abiraterone acetate and enzalutamide in metastatic castration-resistant prostate cancer

BACKGROUND: Abiraterone acetate (AA) and enzalutamide are authorised oral therapies in the treatment of metastatic castration-resistant prostate cancer (mCRPC), which act by inhibiting androgen synthesis. PURPOSE: To compare the effectiveness of AA and enzalutamide in patients with mCRPC. MATERIAL A...

Full description

Saved in:
Bibliographic Details
Published in:Eur J Hosp Pharm
Main Authors: García, AM Sánchez, Mateos, A Andújar, Esquerdo, M Llinares, Irigaray, L Soriano, Torres, R Antón, Ruiz, A Navarro
Format: Artigo
Language:Inglês
Published: BMJ Group 2018
Subjects:
Section 4: Clinical pharmacy services
Online Access:https://ncbi.nlm.nih.gov/pmc/articles/PMC7535815/
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1136/ejhpharm-2018-eahpconf.219
Tags: Add Tag
No Tags, Be the first to tag this record!

Similar Items